Immunology Biosimilars Market Size, Share & Industry Analysis, By Drug Class (TNF-alpha Inhibitors, Interleukin Inhibitors, B-cell/Anti-CD20 Therapies, and Anti-IgE Therapies), By Product (Adalimumab, Infliximab, Etanercept, Rituximab, and Ustekinumab Biosimilars), By Indication (Rheumatology, Gastroenterology, Dermatology, and Allergy & Clinical Immunology), By Age Group (Pediatric and Adults), By Route of Administration (Subcutaneous and Intravenous), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, and Retail & Online Pharmacies), and Regional Forecast, 2026-2034

The global immunology biosimilars market size was valued at USD 15.80 billion in 2025. The market is projected to grow from USD 18.20 billion in 2026 to USD 38.25 billion by 2034, exhibiting a CAGR of 9.73% during the forecast period.

The global market for immunology biosimilar is witnessing an elevated demand due to increasing prevalence of autoimmune and chronic inflammatory diseases, creating a sustained demand for long-term biologic treatment. Healthcare providers and payers are increasingly adopting biosimilars to reduce expenditure and enhance patient access to advanced therapies. The expiry of patents for major biologics, increasing regulatory approvals, and growing physician confidence in biosimilar switching are encouraging pharmaceutical companies to expand their immunology portfolios. These factors are strengthening market competition and supporting the broader adoption of immunology biosimilars across developed and emerging countries.

• For instance, in March 2025, Celltrion launched STEQEYMA, its ustekinumab biosimilar to STELARA, in the U.S. for the treatment of chronic inflammatory conditions, including plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Furthermore, key players, such as Celltrion, Inc., Sandoz Group AG, Samsung Bioepis Co., Ltd., and Biocon Biologics Limited, are actively participating in new product launches, strategic collaborations, acquisitions, and investment initiatives to expand market presence.

IMMUNOLOGY BIOSIMILAR MARKET TRENDS

Growing Shift Toward Biosimilars to Improve Access to Immunology Treatments is a Prominent Trend Observed

A prominent market trend witnessed is a shift toward affordable biological therapies. Healthcare systems are actively seeking to expand treatment access while controlling the high cost of long-term immunology care. Patients with rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis often require continued treatment, making therapy affordability a vital factor in product selection. Biosimilars increase the number of available treatment options and create price competition with reference biologics, enabling hospitals, payers, and physicians to treat a broader patient population. This trend is encouraging pharmaceutical companies to launch biosimilars across multiple immunology indications and strengthen their presence in established biologics markets.

• For instance, in January 2026, Biocon Biologics introduced three immunology biosimilar assets targeting trastuzumab/hyaluronidase, nivolumab, and pembrolizumab. These biologic products are expected to broaden the availability of important immunology therapies through cost-effective biosimilar alternatives.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Growing Patent Expirations and Regulatory Approvals Wave to Drive Market Growth

The increasing patent expirations and regulatory exclusivity for major immunology biologics is creating significant opportunities for biosimilar manufacturers. As exclusivity barriers decline, companies can develop and commercialize alternatives to widely used products such as adalimumab, ustekinumab, infliximab, and etanercept. Additionally, the growing number of regulatory approvals is expanding the availability of biosimilars across varied disease indications. A broader product base increases competition, encourages price reductions, and provides healthcare systems with more options for controlling biologic treatment expenditure. These factors are encouraging pharmaceutical companies to strengthen their biosimilar pipelines and enter multiple immunology indications, thereby driving immunology biosimilars market growth.

• For instance, in September 2024, Fresenius Kabi and Formycon received U.S. FDA approval for OTULFI, an ustekinumab biosimilar to STELARA, in both intravenous and subcutaneous formulations. The product was approved for Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis and has been available in the U.S. from March 2025.

MARKET RESTRAINTS

Intense Competition Based on Prices and Various Product Approvals to Restrain Market Growth

Mature immunology biosimilar molecules including adalimumab, infliximab, and etanercept, face a strong competition from multiple approved products targeting the same reference biologic. To secure hospital tenders, formulary placement, and reimbursement contracts, manufacturers are frequently required to offer substantial discounts and rebates. However, biosimilars continue to comprise complex manufacturing, quality testing, regulatory compliance, and pharmacovigilance costs, limiting the ability of companies to operate sustainably at continuously declining prices. Persistent margin compression can reduce the commercial appeal of mature molecules and discourage further investment. Consequently, excessive price competition may lead to product withdrawals and fewer active suppliers, thereby restraining the long-term revenue growth and sustainability of the market.

• For instance, in November 2024, an ISPOR Europe study reported that biosimilars in the U.K. experienced approximately 60% price erosion from their launch prices, largely due to centralized negotiations and NHS-directed switching policies.

MARKET OPPORTUNITIES

Expansion into Next-Wave Immunology Molecules and New Indications to Create Growth Opportunities

The market has significant growth potential beyond mature TNF-α and anti-CD20 products, as manufacturers increasingly target newer biologics. These reference biologics are used across a broader range of rheumatology, dermatology, gastroenterology, respiratory, and allergic conditions and continue to have high treatment costs in healthcare systems. Compared with mature biosimilar categories, several next-wave molecules have fewer competitors, providing opportunities for first-mover advantages, stronger pricing, and faster market penetration. Expanding biosimilar development into indications such as allergic asthma, chronic spontaneous urticaria, nasal polyps, juvenile arthritis, and inflammatory bowel disease can also increase the addressable patient population. Therefore, companies that are building diversified pipelines across emerging immunology targets and indications are expected to capture new revenue opportunities and reduce their dependence on highly competitive mature molecules.

• For instance, in February 2022, Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. FDA accepted the Biologic License Application (BLA) for HLX11, an investigational biosimilar of Perjeta (pertuzumab).

MARKET CHALLENGES

Regulatory Uncertainty and Clinical Development Burden to Challenge New Product Entry

The development of immunology biosimilars requires extensive analytical comparability, pharmacokinetic, immunogenicity, and safety. Differences in clinical data, interchangeability, reference-product sourcing, and manufacturing requirements across regulatory markets can increase development complexity and create uncertainty regarding approval timelines. These challenges are greater for complex monoclonal antibodies and next-generation immunology molecules, where minor manufacturing variations may affect product quality and require additional supporting evidence. Therefore, smaller biosimilar developers may postpone or discontinue pipeline programs, limiting new product entry and market competition.

• For instance, in April 2023, Alvotech received a Complete Response Letter from the U.S. FDA for AVT02, its high-concentration adalimumab biosimilar candidate. The agency stated that deficiencies identified during the reinspection of the company’s manufacturing facility had to be resolved before approval, delaying the product’s entry into the U.S. market and highlighting the regulatory and manufacturing risks involved in biosimilar commercialization.

Segmentation Analysis

By Drug Class

Broad Indication Coverage of Autoimmune Diseases and High Prescription Volumes have Supported TNF-α Inhibitors’ Dominance

Based on the drug class, the market is categorized into TNF-alpha inhibitors, interleukin inhibitors, B-cell/anti-CD20 therapies, anti-IgE therapies, and others.

TNF-α inhibitors segment dominated the market as these therapies are used across several high-burden autoimmune diseases. This drug class includes widely prescribed biologics such as adalimumab, infliximab, and etanercept. Their early introduction has created strong physician familiarity, established treatment guidelines, and large populations receiving long-term therapy. The availability of several competing biosimilars has further encouraged formulary switching and improved treatment affordability. These factors have generated higher prescription volumes for TNF-α inhibitor biosimilars compared with newer immunology drug classes.  

• For instance, in May 2025, Samsung Bioepis and Organon received an interchangeability designation from the U.S. FDA for all high- and low-concentration presentations of Humira. The designation supports pharmacy-level substitution, subject to state laws, and strengthens the adoption of TNF-α inhibitor biosimilars.

The Anti-IgE therapies segment is expected to grow at a CAGR of 16.61% over the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Product

Long-standing Clinical Use and Broad Therapeutic Coverage Positioned Infliximab Biosimilars as the Leading Product

Based on product, the market is segmented into adalimumab biosimilars, infliximab biosimilars, etanercept biosimilars, rituximab biosimilars, ustekinumab biosimilars, tocilizumab biosimilars, omalizumab biosimilars, golimumab biosimilars, and others.

In 2025, the infliximab biosimilars segment captured the most significant share in the market. The dominance is owing to its early entry into the monoclonal antibody biosimilars space and extensive clinical use across rheumatology and gastroenterology. Their long market presence has increased physician’s confidence in switching patients from the reference product and has generated substantial real-world evidence supporting their use. Also, centralized hospital tenders and institutional procurement programs have accelerated their adoption in several emerging markets. This combination of broad indications, established clinical acceptance, and regular hospital-based utilization has supported the segment’s leading share.

• For instance, in 2026, Celltrion secured a national tender in Norway for its liquid formulation of Remsima IV, with the company expecting the product to capture approximately 35% of the country’s intravenous infliximab market.

The ustekinumab biosimilars segment is projected to grow at a 23.24% CAGR during the forecast period.

By Indication

Prolonged Disease-Modifying Treatment Need for Chronic Inflammatory Joint Diseases Sustained Rheumatology’s Dominance

Based on indication, the market is segmented into rheumatology, gastroenterology, dermatology, allergy & clinical immunology, systemic autoimmune diseases & vasculitis, ophthalmic immunology, and others.

The rheumatology segment dominated the market based on indication. Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile inflammatory arthritis require prolonged disease-modifying treatment. Patients who do not attain adequate disease control with conventional therapies frequently progress to biologics, creating continued demand for affordable biosimilar options. Rheumatology was also one of the earliest therapeutic areas to adopt biosimilars, resulting in greater physician experience with product switching and long-term safety and efficacy monitoring. Consequently, the combination of a large treated population and repeated long-term dosing has supported higher revenue contribution from rheumatology.

• For instance, in June 2024, the European Commission approved Biogen’s TOFIDENCE, an intravenous tocilizumab biosimilar, for indications including moderate-to-severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

The allergy & clinical immunology segment is projected to grow at a CAGR of 16.22% during the forecast period.

By Age Group

Prevalence of Progressive Diseases Amongst Adult Patient Population to Support Segment’s Governance

Based on the age group, the market is segmented into pediatric and adult.

Based on age group, the adult segment dominated the market as most of the major autoimmune and chronic inflammatory diseases treated with biosimilars are diagnosed and actively managed among working-age and older adults. Adult patients are more likely to experience persistent or progressive disease requiring escalation from conventional medicines to biologic therapies. Several immunology biosimilars also carry broad adult labels across rheumatology, dermatology, and gastroenterology. These factors have created a substantially larger commercial patient pool for adult immunology biosimilars.

• For instance, in February 2024, Alvotech received approval from the U.S. for its SIMLANDI for multiple adult indications, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.

The pediatric segment is projected to grow at a CAGR of 12.73% during the forecast period.

By Route of Administration

Convenience of Flexible Dosing and Reduced Infusion Burden Favored Subcutaneous Products

Based on the route of administration, the market is segmented into subcutaneous, intravenous, and others.

In 2025, the subcutaneous segment dominated the market as this route of administration provides greater convenience than repeated intravenous infusions for patients requiring long-term immunology treatment. The route also supports more flexible dosing and can improve patient’s willingness to remain on chronic therapy. Manufacturers are increasingly introducing high-concentration, citrate-free, and ready-to-use subcutaneous biosimilars to provide an administration experience compared with reference biologics. Growing availability of patient-friendly presentations has therefore increased the prescription and commercial uptake of subcutaneous biosimilars.

• For instance, in July 2024, Fresenius Kabi launched the subcutaneous formulation of TYENNE, its tocilizumab biosimilar, in the U.S. The launch followed the introduction of its intravenous formulation and expanded access to a more convenient administration option for chronic autoimmune diseases.

The others segment is projected to grow at a CAGR of 8.64% over the study period.

By Distribution Channel

Centralized Procurement and Specialist-led Treatment Sustained Hospital Pharmacies’ Leadership

Based on the distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, drug stores & retail pharmacies, and online pharmacies.

The hospital pharmacies segment dominated the market as biologic treatment is commonly initiated, prescribed, and monitored by clinical immunologists working within hospitals and specialty care centers. Intravenous products require controlled preparation and administration in supervised clinical settings, directing a significant share of procurement through hospital pharmacies. These pharmacies also manage cold-chain storage, institutional formularies, reimbursement documentation, and biosimilar switching programs. Hospitals can negotiate large-volume tenders and purchasing agreements, which further encourages the selection of lower-cost biosimilars. Therefore, institutional purchasing and the continued use of infusion-based products have supported the leading position of hospital pharmacies.

• For instance, in February 2024, the U.S. Department of Veterans Affairs exclusively selected Organon and Samsung Bioepis’ HADLIMA to replace Humira on its national formulary. The decision demonstrates the importance of centralized institutional formulary selection in driving biosimilar procurement and patient switching.

The specialty pharmacies segment is projected to grow at a CAGR of 12.57% over the forecast period.

Immunology Biosimilars Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America was valued at USD 4.08 billion in 2024 and maintained its growth momentum by securing the second position in 2025 with USD 4.81 billion. The North American market growth is supported by increasing biosimilar launches, loss of exclusivity for major immunology biologics, and rising payer pressure to reduce treatment costs. Expanding interchangeability designations and formulary switching are improving adoption. High autoimmune disease treatment and strong biologics spending further support regional demand.

U.S. Immunology Biosimilars Market

Given North America's substantial contribution and the U.S. dominance in the region, the U.S. market is estimated at around USD 5.13 billion in 2026, accounting for roughly 28.19% of the global market.

Europe

Europe secured the leading immunology biosimilars market share and is projected to grow at CAGR of 6.97% over the coming years, with leading growth rate among all regions, and with an expected valuation to reach USD 6.31 billion by 2026. The region continues to grow due to established biosimilar regulations, centralized tender systems, and strong physician experience with switching. National healthcare systems actively promote lower-cost biosimilars to control biologic expenditure. New approvals for ustekinumab, tocilizumab, and other next-wave molecules are expanding the regional market growth.

U.K Immunology Biosimilars Market

The U.K. market is estimated at USD 0.87 billion in 2026, accounting for roughly 4.80% of the global market.

Germany Immunology Biosimilars Market

Germany's market is projected to reach approximately USD 1.36 billion in 2026, equivalent to around 7.48% of the global market.

Asia Pacific

Asia Pacific accounted for the third-largest share in the market in 2025 and is estimated to reach USD 4.94 billion in 2026. The market is growing due to a large patient population, increasing diagnosis of autoimmune diseases, and rising access to biologic therapies.

Japan Immunology Biosimilars Market

The Japanese market in 2026 is estimated at around USD 1.04 billion, accounting for approximately 5.69% of the global market.

China's Immunology Biosimilars Market

China's market is projected to be among the largest globally, with 2026 revenues estimated at around USD 1.17 billion, accounting for approximately 9.71% of global sales.

India Immunology Biosimilars Market

The Indian market is estimated at around USD 0.85 billion in 2026, accounting for roughly 4.68% of global revenue.

Latin America and the Middle East & Africa

The Latin America and Middle East & Africa regions are expected to witness moderate growth in this market during the forecast period. The market for Latin America is estimated to reach a valuation of USD 0.81 billion. Expanding regulatory approvals and local commercialization partnerships are improving product availability. Rising treatment access for rheumatoid arthritis, psoriasis, and inflammatory bowel disease is supporting market expansion. In the Middle East & Africa, the GCC is set to reach USD 0.23 billion in 2026.

South Africa Immunology Biosimilars Market

The South African market is projected to reach approximately USD 0.12 billion by 2026, accounting for roughly 0.67% of global revenue.

COMPETITIVE LANDSCAPE

Key Industry Players

Product Portfolio Expansion and Strategic Partnerships among Key Companies to Intensify Market Competition

The strong presence of established biosimilar manufacturers, global pharmaceutical companies, and regional biologics developers characterizes the global immunology biosimilars market. Companies are focusing on strengthening their product portfolios through new product launches, interchangeability designations, geographic expansion, and development of next-wave molecules such as ustekinumab, omalizumab, tocilizumab, golimumab, and secukinumab biosimilars. Strategic licensing and commercialization agreements are also helping developers access established regulatory, distribution, and physician networks across major markets.

• For instance, in February 2025, Bio-Thera Solutions collaborated with Intas Pharmaceuticals for BAT2506, its proposed golimumab biosimilar, in the U.S. Under the agreement, Bio-Thera retained responsibility for development, manufacturing, and supply, while Intas’ Accord BioPharma division became responsible for U.S. commercialization.

Major players such as Celltrion, Sandoz, Samsung Bioepis, Biogen, Organon, Amgen, Pfizer, Fresenius Kabi, and Biocon Biologics, are actively competing through portfolio diversification, regulatory approvals, partnerships, product differentiation, and country-specific launches. Companies with broad immunology portfolios, integrated manufacturing capabilities, strong commercialization partners, and established hospital and payer access are expected to maintain leading position in the market.

LIST OF KEY IMMUNOLOGY BIOSIMILARS COMPANIES PROFILED

• Celltrion, Inc. (South Korea)
• Sandoz Group AG (Switzerland)
• Samsung Bioepis Co., Ltd. (South Korea)
• Biogen Inc. (U.S.)
• Organon & Co. (U.S.)
• Amgen Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Fresenius Kabi AG (Germany)
• Biocon Biologics Ltd. (India)
• Alvotech (Luxembourg)
• STADA Arzneimittel AG (Germany)

KEY INDUSTRY DEVELOPMENTS

• February 2026: STADA in collaboration with Bio-Thera Solutions received a marketing authorization from the European Commission for their Gotenfia (golimumab) biosimilar referencing Simponi. The reference product was indicated for several chronic inflammatory autoimmune diseases.
• November 2025: Celltrion, Inc. received marketing authorization from the European Commission (EC) for Remsima IV (intravenous) liquid formulation—the first liquid formulation of IV infliximab. The product is approved in 100 mg and 350 mg vials.
• November 2025: Bio-Thera Solutions entered into an exclusive commercialization and license agreement with Dr. Reddy’s Laboratories Ltd. for BAT2306, a proposed biosimilar candidate to Cosentyx (secukinumab).
• August 2025: Gedeon Richter announces it has received marketing authorization from the European Commission (EC) for BAT2206 (ustekinumab), a biosimilar referencing Stelara.
• August 2025: Bio-Thera Solutions collaborated with STADA Arzneimittel AG to extend their biosimilars alliance to cover tocilizumab, an immunosuppressant monoclonal antibody indicated for certain inflammatory conditions.

REPORT COVERAGE

The immunology biosimilars market report provides a detailed assessment of all market segments, highlighting key drivers, trends, opportunities, restraints, and challenges shaping industry growth. It also covers technological advancements, major industry developments, market share analysis, and comprehensive profiles of leading companies. The report also evaluates drug class trends, age group, branded and generic adoption, age group dynamics, and distribution channel performance across key regions. It includes global market analysis, including pipeline developments, regulatory approvals, product launches, pricing and reimbursement trends, and competitive strategies adopted by leading pharmaceutical companies. The study also highlights regional growth patterns across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, along with key factors supporting adoption in each region.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation 

Research Methodology:

1.Bottom Up Approaches

Approach 1:  Revenues and Market Share of Major Immunology Biosimilars

• Collection of immunology biosimilar revenues from annual reports, SEC filings, investor presentations, earnings releases, and disclosures of key companies such as Celltrion, Sandoz, Samsung Bioepis, Biogen, Organon, Amgen, Pfizer, Fresenius Kabi, Biocon Biologics, and Alvotech.
• Estimation of company market share based on product revenues, geographic presence, product availability, tender participation, commercialization partnerships, and immunology biosimilar portfolio breadth.
• Separation of immunology-related revenues from oncology, hematology, and other non-immunology applications of multi-indication biosimilars.
• Triangulation of company-level revenues with regional biosimilar penetration, prescription adoption, tender volumes, and manufacturer-level prices to derive the global market estimate.

Approach 2: Product-Level Sales Analysis

• Identification of commercially launched adalimumab, infliximab, etanercept, rituximab, ustekinumab, tocilizumab, omalizumab, golimumab, and other immunology biosimilars.
• Collection of product-level sales, prescription volumes, treatment units, dosage strengths, pack sizes, vials, prefilled syringes, pens, and autoinjector utilization.
• Estimation of manufacturer-level average selling prices using company disclosures, public procurement prices, hospital tenders, reimbursement databases, and ex-factory prices.
• Multiplication of product volumes by manufacturer-level selling prices, followed by aggregation across countries and regions to estimate the global market.
• Assessment of expected product launches, indication expansions, interchangeability designations, and commercialization partnerships affecting future adoption.

Approach 3:  Epidemiology Model

• Assessment of diagnosed and treatment-eligible patient populations across rheumatology, gastroenterology, dermatology, allergy & clinical immunology, systemic autoimmune diseases & vasculitis, and ophthalmic immunology.
• Mapping of biologic-treated patients to major biosimilar molecules based on indication eligibility, biologic penetration, biosimilar adoption, and originator-to-biosimilar switching rates.
• Application of indication-specific dosage, treatment frequency, induction and maintenance schedules, adherence, and average treatment duration.
• Multiplication of treated biosimilar patients by annual treatment units and manufacturer-level cost per patient to estimate country and regional markets.
• Summation of regional estimates to arrive at the global immunology biosimilars market.

2. Top Down Approaches

Approach 1: Analysis of Parent Market

• Analysis of the global biosimilars market and estimation of the proportion attributable to immunology biosimilars based on marketed molecules, biologic treatment expenditure, therapeutic utilization, and product availability.
• Assessment of the immunology biologics market across rheumatology, gastroenterology, dermatology, allergy, vasculitis, and ophthalmic immunology indications.
• Adjustment for originator biologic share, biosimilar penetration, manufacturer-level price discounts, regional launch timing, and regulatory adoption.
• Allocation of the parent-market estimate across regions, products, indications, and routes of administration to derive the global immunology biosimilars market.

3. List of Key Sources

• S. FDA and FDA Purple Book
• European Medicines Agency and European Commission
• PMDA and Ministry of Health, Labour and Welfare, Japan
• NMPA and Center for Drug Evaluation, China
• CDSCO and Similar Biologics Guidelines, India
• Therapeutic Goods Administration and Australian Register of Therapeutic Goods
• Health Canada, CMS, NHS, and national reimbursement agencies
• International Generic and Biosimilar Medicines Association
• Medicines for Europe, Biosimilars Council, and Association for Accessible Medicines
• PubMed, ClinicalTrials.gov, treatment guidelines, disease registries, and real-world studies
• Company annual reports, SEC filings, investor presentations, product labels, press releases, approval announcements, and commercial partnership disclosures
• Public procurement databases, hospital tenders, reimbursement prices, prescription volumes, and biosimilar utilization reports

4. Primary Interviews

Supply Side Interviews: 60%

• Key Respondents: Discussions with biosimilar manufacturers, developers, commercialization partners, distributors, contract manufacturers, and industry experts.
• Interviews are used to validate market size, manufacturer prices, product volumes, regional penetration, tender participation, commercialization rights, competitive positioning, and expected launches.
• Key respondents included business development executives, product managers, commercial heads, market-access teams, sales leaders, regulatory professionals, and manufacturing experts.

Demand Side Interviews: 40%

• Key Respondents: Discussions with rheumatologists, gastroenterologists, dermatologists, allergists, immunologists, hospital pharmacists, specialty pharmacists, procurement teams, payers, and formulary decision-makers.